AUAbdulhamid Sani Usman

Abdulhamid Sani Usman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdulhamid Sani Usman has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ficus deltoidea attenuates tau hyperphosphorylation and neurodegeneration in a -galactose and aluminum-induced Alzheimer’s disease-like rat model

    by Sushmitaa Dhevii Manoharan, Abdulhamid Sani Usman, Che Mohd Nasril Che Mohd Nassir, Hafizah Abdul Hamid, Nur Fariesha Md Hashim, Anwar Norazit, Jayakumar Murthy, Zaw Myo Hein, Murizal Zainol, Samaila Musa Chiroma, et al.


  • Open Access

    Neuroprotective Mechanisms of Ficus deltoidea in an Alzheimer’s Disease-Like Rat Model: Targeting Tau Hyperphosphorylation Through Glycogen Synthase Kinase-3 Beta and Protein Phosphatase 2A Regulation

    by Sushmitaa Dhevii Manoharan, Abdulhamid Sani Usman, Hafizah Abdul Hamid, Che Mohd Nasril Che Mohd Nassir, Manraj Singh Cheema, Muhammad Danial Che Ramli, Mohamad Aris Mohd Moklas, Muhammad Zulfadli Mehat

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterised by memory loss, neurodegeneration, amyloid plaque accumulation and tau hyperphosphorylation. Dysregulation of glycogen synthase kinase-3β (GSK-3β) and protein phosphatase 2 A (PP2A) plays a pivotal role in tau pathology, contributing to synaptic dysfunction and memory impairment. Current AD medications offer limited palliative care, underscoring the need for multifaceted therapeutic strategies. Ficus deltoidea (FD), a medicinal plant renowned for its antioxidant and anti-inflammatory properties, has demonstrated neuroprotective effects, however, its specific role in modulating tau-associated proteins in AD remains underexplored. Thus, this study investigated the neuroprotective properties of FD on the spatial learning and memory, hippocampal histology and the levels of GSK-3β and PP2A in an AD-like rat model. Male rats were administered D-galactose (60 mg/kg) and aluminum chloride (200 mg/kg) for 11 weeks to induce AD-like characteristics. Rats were divided into six groups: control, AD model, donepezil-treated (1 mg/kg), and FD-treated groups receiving 50, 100 and 200 mg/kg of FD extract. Behavioural performances were assessed using the open field test (OFT) and modified elevated plus maze (mEPM). FD administration significantly improved spatial learning and memory in AD-like rats. Nissl staining revealed an increase in viable hippocampal granule neurons in FD-treated rats. Immunoblot analysis reported a reduction in GSK-3β and an increase in PP2A levels, suggesting reduced hippocampal tau phosphorylation. These findings indicate that FD confers neuroprotection by restoring the kinase-phosphatase balance, which in turn enhances hippocampal neuronal survival and memory, thereby supporting its potential as a phytotherapeutic agent for AD intervention.


  • Neuroprotective Effects of Ficus deltoidea in Alzheimer’s Disease-Like Rat Model: Insights from Behavior, Histology, and Amyloid Pathology

    by Abdulhamid Sani Usman, Sushmitaa Dhevii Manoharan, Che Mohd Nasril Che Mohd Nassir, Hafizah Abdul Hamid, Zaw Myo Hein, Anwar Norazit, Jayakumar Murthy, Murizal Zainol, Mohd Amir Kamaruzzaman, Samaila Musa Chiroma, et al.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline, memory impairment, and accumulation of amyloid-β (Aβ) plaques. While current treatments offer limited efficacy, medicinal plants such as Ficus deltoidea (FD), a traditional remedy, have shown promise due to their neuroprotective and anti-inflammatory properties. An AD-like phenotype was induced in male Wistar rats using D-galactose and aluminum chloride over 70 days. FD extract was administered orally at 50, 100, and 200 mg/kg. Spatial memory was evaluated using the T-maze test. Histological analyses of the hippocampi’s Cornu Ammonis 1 and 3 (CA1 and CA3) regions were conducted via hematoxylin and eosin (H&E) staining, and Aβ plaques deposition was assessed with Congo red. Enzyme-linked immunosorbent assay (ELISA) was used to quantify hippocampal levels of Aβ (1–42) and β-secretase-1 (BACE-1). FD treatment significantly enhanced spatial memory, preserved pyramidal neuron integrity in CA1 and CA3, and reduced amyloid plaque formation. Biochemically, FD markedly decreased hippocampal Aβ (1–42) and BACE-1 concentrations in a dose-dependent manner. Thus, FD exhibits multi-target neuroprotective effects in an AD-like model, potentially via modulation of amyloidogenic pathways. Further studies are warranted to explore its mechanisms and therapeutic potential in other brain regions implicated in AD.